|
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
Jul 31, 2026 Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation Jul 30, 2026 Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD) Jul 30, 2026 Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? Jul 30, 2026 Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial Jul 30, 2026 Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL Jul 29, 2026 Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial Jul 29, 2026 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Jul 29, 2026 Rethinking Regulatory Protections for Accelerated Approvals With Supplementary Indications Jul 29, 2026 He Was Always There Jul 28, 2026 Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial Jul 27, 2026 SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer Jul 27, 2026 Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Jul 27, 2026 Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors Jul 27, 2026 Anti-TIGIT in PD-L1–High Advanced Non–Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward Jul 27, 2026 Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) Jul 27, 2026 |
Taking Responsibility Journal of Clinical Oncology, Volume 44, Issue 24, Page 2353-2355, August 2026. <br/> 2026-08-20T07:00:00Z Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program Journal of Clinical Oncology, Volume 44, Issue 24, Page 2303-2315, August 2026. <br/> 2026-08-20T07:00:00Z Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial Journal of Clinical Oncology, Volume 44, Issue 24, Page 2329-2340, August 2026. <br/> 2026-08-20T07:00:00Z Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) Journal of Clinical Oncology, Volume 44, Issue 24, Page 2341-2352, August 2026. <br/> 2026-08-20T07:00:00Z Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study Journal of Clinical Oncology, Volume 44, Issue 24, Page 2271-2277, August 2026. <br/> 2026-08-20T07:00:00Z Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848 Journal of Clinical Oncology, Volume 44, Issue 24, Page 2316-2328, August 2026. <br/> 2026-08-20T07:00:00Z Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1 Journal of Clinical Oncology, Volume 44, Issue 24, Page 2278-2289, August 2026. <br/> 2026-08-20T07:00:00Z High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis Journal of Clinical Oncology, Volume 44, Issue 24, Page 2290-2302, August 2026. <br/> 2026-08-20T07:00:00Z Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? Journal of Clinical Oncology, Volume 44, Issue 24, Page 2266-2270, August 2026. <br/> 2026-08-20T07:00:00Z Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection Journal of Clinical Oncology, Volume 44, Issue 24, Page 2356-2356, August 2026. <br/> 2026-08-20T07:00:00Z Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology, Volume 44, Issue 24, Page 2358-2359, August 2026. <br/> 2026-08-20T07:00:00Z Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE) Journal of Clinical Oncology, Volume 44, Issue 24, Page 2361-2361, August 2026. <br/> 2026-08-20T07:00:00Z Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis Journal of Clinical Oncology, Volume 44, Issue 24, Page 2361-2362, August 2026. <br/> 2026-08-20T07:00:00Z Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model Journal of Clinical Oncology, Volume 44, Issue 24, Page 2362-2362, August 2026. <br/> 2026-08-20T07:00:00Z Reply to: Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection Journal of Clinical Oncology, Volume 44, Issue 24, Page 2357-2358, August 2026. <br/> 2026-08-20T07:00:00Z Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology, Volume 44, Issue 24, Page 2359-2360, August 2026. <br/> 2026-08-20T07:00:00Z |
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. 2026-08-20
Myeloproliferative Neoplasms This review summarizes the pathogenesis and treatment of myeloproliferative neoplasms, highlighting the role of driver mutations, inflammation, and emerging targeted therapies that may achieve durable disease modification. 2026-08-20
Marijuana Rescheduling — A Game Changer for Research? A proposed reclassification of medical marijuana products as Schedule III drugs would address only two of the three key barriers to research on marijuana’s safety and effectiveness for various indications. 2026-08-20
Severe Plasmodium falciparum Malaria An 82-year-old man was brought to the ED after being “found down.” One week earlier, he had returned from a 1-month visit to Chad. A peripheral-blood smear showed ring-form trophozoites within erythrocytes. 2026-08-20
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. 2026-08-13
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. 2026-08-13
Warthin Tumors A 55-year-old man with a smoking history of 10 pack-years presented with 2 years of an enlarging, painless lump below his right ear. A previously unnoticed smaller mass in the left parotid gland was seen on examination. 2026-08-13
Disseminated Fusariosis A 61-year-old man with prolonged neutropenia after chemotherapy for AML was evaluated for persistent fever despite antimicrobial therapy. Physical examination was notable for a skin macule with central necrosis on the chest. 2026-08-13
PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma In a child with advanced nephroblastoma, T-cell therapy targeting preferentially expressed antigen in melanoma led to a 69% tumor reduction, with molecular, metabolic, and histologic evidence of complete remission at 200 days. 2026-08-13
Perioperative Apalutamide in High-Risk Localized Prostate Cancer In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. 2026-08-06
A Watershed Moment in the Perioperative Treatment of Prostate Cancer Current curative-intent management of high-risk localized prostate cancer (nonmetastatic prostate cancer with extraprostatic extension or seminal-vesicle invasion, a histologic Gleason score of ≥8 [on a scale from 6 to 10, with higher scores indicating more aggressive disease], or a serum prostate-specific antigen level of ≥20 ng per milliliter) involves either... 2026-08-06
Consumed with Inflammation A 60-year-old woman with stage II triple-negative breast cancer presented to the ED with a weeklong history of fevers, rigors, malaise, nonproductive cough, and nausea. 2026-08-06
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer In patients with metastatic prostate cancer with gene alterations, talazoparib–enzalutamide led to better progression-free survival outcomes than placebo–enzalutamide but with more serious adverse events. 2026-07-30
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. 2026-07-30
Platelet-Activating Anti–Platelet Factor 4 Disorders This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies. 2026-07-30
Precision Intensification in Metastatic Prostate Cancer The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated... 2026-07-30
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules The treatment landscape of multiple myeloma has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology, refined patient stratification, the integration of new prognostic biomarkers, and sustained therapeutic innovation. Today, most patients receive proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies as frontline... 2026-07-30
Cross-Correction in HSC Gene Therapy for Metachromatic Leukodystrophy This study supports enzymatic cross-correction of neurons and oligodendrocytes by atidarsagene autotemcel, a gene therapy that prevents or slows neurodegeneration in children with early-onset metachromatic leukodystrophy. 2026-07-30
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. 2026-07-23
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. 2026-07-23
|
|
|
| |||
|
[Editorial] Beyond cancer: The Right to be Forgotten
In Germany, politicians are pressing the government to end discrimination against people in remission from cancer. Germany remains among the European outliers in obstructing a fresh start for former patients. A petition campaigning under the slogan, “Healed. And Yet Disadvantaged”, has gathered over 56 000 signatures. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer The adoption of total mesorectal excision (TME) has significantly reduced the risk of locoregional recurrence in patients with rectal cancer. However, this reduction comes at the cost of substantial treatment-related morbidity, including permanent stoma formation and long-term impairment of bowel, urinary, and sexual function that adversely impact quality of life (QOL) and functionality.1 As such, management has evolved toward risk-adapted, patient-centred strategies, including selective organ preservation that is oncologically safe and associated with better QOL. Sun, 23 Aug 2026 22:30:02 +0000
[Comment] Radiotherapy dose intensification for high-risk prostate cancer—what is gained? Can a modest increase in radiotherapy dose make a difference for a patient with high-risk prostate cancer? In The Lancet Oncology, Christophe Hennequin and colleagues present results from the GETUG-AFU 18 trial,1 which enrolled 505 patients across 25 centres in France to answer this important and relevant question. Participants were randomly assigned (1:1) to receive 70 Gy or 80 Gy to the prostate, along with 3 years of androgen deprivation therapy (ADT). The higher radiotherapy dose improved biochemical or clinical progression-free survival (the primary outcome) from 88·1% to 91·4% at 5 years and from 72·2% to 83·6% at 10 years (stratified hazard ratio 0·56, 95% CI 0·40–0·78). Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Beyond visual tumour-infiltrating lymphocytes assessment Stromal tumour-infiltrating lymphocytes (sTILs) have become one of the most clinically informative immune biomarkers in breast cancer,1 associated with improved response to systemic therapy and favourable long-term outcomes.2,3 Reproducibility is not the obstacle to their use. In a secondary analysis of the APHINITY trial in The Lancet Oncology, Luis E Lara González and colleagues4 found a high interobserver reproducibility among five pathologists scoring 262 cases to international guidelines.5 However, scoring requires expert pathologists, quality-assured haematoxylin and eosin slides, and time, which are unevenly distributed across health systems. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Afghan women's cancer crisis deserves its own response Non-communicable diseases (NCDs) already account for an estimated 43% of all deaths in Afghanistan1 and are projected to exceed 60% by 2030, mainly among women. However, access to cancer care remains critically limited—Afghanistan has only two functioning cancer treatment centres, both in Kabul (Jamhuriat Hospital and the newly opened National Cancer Diagnosis and Treatment Hospital), for more than 40 million people, and neither offers radiotherapy.2 These gaps contribute to delayed diagnosis, poor outcomes, and avoidable mortality, and highlight the urgent need to strengthen cancer prevention, detection, and treatment nationwide. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Cancer care in Canada Canada's cancer care system has achieved substantial progress through advances in cancer prevention, screening, early detection, and treatment, including targeted therapies and immunotherapy.1 Although both the age-standardised incidence rate and age-standardised mortality rate (ASMR) continue to decline, an estimated 254 100 Canadians will be diagnosed with cancer and an estimated 87 900 will die from the disease in 2026.2 Tue, 01 Sep 2026 00:00:00 -0700
[Correspondence] Closing the gap in southeast Asia's diagnostic molecular oncology testing We welcome The Lancet Oncology Commission highlighting the global cancer workforce crisis, which projects a shortage of 9·47 million diagnostic (pathology and imaging) specialists in Asia by 2050 and identifies pathologists as yielding the highest return on investment in the region (US$35·4 per $1 invested).1 Although the Commission focuses primarily on Africa and Latin America, southeast Asia offers a compelling example of how diagnostic workforce shortages and limited laboratory capacity directly constrain access to precision oncology. Tue, 01 Sep 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 686–98 Brunt AM, Cafferty FH, Kirby AM, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy. Lancet Oncol 2026; 27: 686–98—The appendix of this Article has been corrected as of Aug 24, 2026. Tue, 01 Sep 2026 00:00:00 -0700
[News] UK study to report cancer risk in armed services personnel The UK Government has announced it is to conduct a study into cancer risk in armed services personnel, both past and present. The UK's Ministry of Defence says the study is part of its efforts to improve the long-term health of those who serve and have served in the armed services. The UK-wide epidemiological study (covering all four nations) will examine cancer incidence among those who have served since 1990, including some 1·4 million currently serving and veterans. No personnel will need to take action to be included in the study, as it will use existing records held in by the country's National Health Service (NHS). Thu, 23 Jul 2026 22:30:01 +0000
[News] Sweden plans to restrict PFAS On July 23, 2026, the Government of Sweden announced plans to prohibit perfluoroalkyl and polyfluoroalkyl substances (PFAS), also called forever chemicals, in certain consumer products such as clothing, footwear, cosmetics, and kitchen utensils starting Jan 1, 2028. This plan will make Sweden one of the latest European countries to propose national restrictions ahead of the broader EU legislation. Thu, 30 Jul 2026 22:30:02 +0000
[News] CARICOM moves towards regional framework for cancer The Caribbean Community (CARICOM) is moving towards a regional framework for cancer care after calling for stronger cooperation between members, although questions remain over funding, governance, and implementation. The call followed the 14th Annual Caribbean Association for Oncology and Hematology (CAOH) Scientific Conference, held in Trinidad and Tobago, on July 17–19, 2026. Thu, 30 Jul 2026 22:30:02 +0000
[News] UK–Japan research collaboration for cancers in children and young people On July 28, 2026, organisations from the UK and Japan announced a partnership that will provide funding opportunities for international collaborative clinical trials aimed at developing innovative treatments for cancers affecting children and young people (CYP). Thu, 06 Aug 2026 22:30:02 +0000
[News] 2030 hepatitis elimination targets might be missed in Europe Europe is set to miss the WHO target to eliminate viral hepatitis as a public health threat by 2030 despite progress in screening because of gaps in vaccination and reaching key populations, according to the European Centre for Disease Prevention and Control (ECDC). Thu, 06 Aug 2026 22:30:02 +0000
[News] New liver cancer medicine fast-tracked by UK Government A new medicine for hepatocellular liver cancer has been granted an Innovation Passport through the UK's Innovative Licensing and Access Pathway (ILAP), the Medicines and Healthcare products Regulatory Agency (MHRA) announced last week. Thu, 13 Aug 2026 22:30:01 +0000
[News] Saint Lucia launches national cancer registry The eastern Caribbean island nation of Saint Lucia has launched a national population-based cancer registry, 7 years after first announcing plans to establish one, as it seeks to replace fragmented records and modelled estimates with systematic data on cancer incidence. The registry comes as the country develops a cancer control plan, but its usefulness will depend on complete case reporting, specialist staff, sustained financing, and whether the resulting data influence policy making. Thu, 13 Aug 2026 22:30:02 +0000
[Perspectives] A polycrisis in cancer care: Cuba's system under the oil blockade Cuba's cancer care programme is facing a polycrisis, in which disruptions in energy supply, pharmaceutical access, and technological capacity interact and reinforce one another. The strain is most visible at two of its most resource-intensive nodes: the supply of cytostatic drugs for chemotherapy and the operational readiness of radiotherapy. Both have long been limited by restricted access to pharmaceutical markets, equipment, and spare parts under the decades-long US trade embargo. The oil blockade imposed on Jan 29, 2026 (figure 1), has converted these chronic constraints into an acute systemic breakdown. Fri, 19 Jun 2026 22:30:01 +0000
[Perspectives] Rethinking failure and tolerance in oncology When I received my first chemotherapy tablets, the literature was terrifying: the insert warned against touching the pills or my bodily fluids without gloves. The bag read CAUTION next to a neon yellow biohazard symbol. Shared bathrooms were discouraged. I thought: if this treatment is so dangerous, why am I supposed to ingest it? Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement versus TACE. These findings support a STRIDE-based regimen as a potential new treatment option for people with embolisation-eligible HCC; additional follow-up is being conducted for final analysis of overall survival across treatment groups. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial Ivonescimab plus chemotherapy showed a clinically meaningful and statistically significant progression-free survival benefit in patients with EGFR-mutated NSCLC after progression on EGFR-TKI therapy. The clinical benefit and lack of new safety signals of ivonescimab with chemotherapy support the potential for the combination as a new treatment option in this patient population. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial For patients with resected ALK-positive NSCLC, adjuvant alectinib had a manageable safety profile; HRQoL improved and was maintained over 2 years of active treatment. Together with the disease-free survival benefit seen in ALINA, these data support adjuvant alectinib as an important new standard-of-care for patients with resected ALK-positive NSCLC. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial These early results support a response-adapted organ-preservation approach, with LCCRT appearing more effective than SCRT at 12 months. Organ-preservation might also reduce treatment-related toxicity compared with primary TME. Longer follow-up is needed for the prespecified 30-month endpoint and definitive functional and oncological outcomes. Sun, 23 Aug 2026 22:30:02 +0000
[Articles] Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial The combination of ifebemtinib and garsorasib showed promising anticancer activity and manageable safety profile in previously treated patients with KRASG12C-mutated metastatic colorectal cancer. Although the improvement in response rate did not reach statistical significance in the randomised study, these findings support further evaluation of ifebemtinib plus garsorasib in this population. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial SHR-A2102 demonstrated a safety profile consistent with its topoisomerase I inhibitor payload and showed promising activity in patients with various advanced solid tumours who had previously received anti-cancer treatment. A range of active dose was identified in various tumour types. Several trials are ongoing to evaluate SHR-A2102, either as monotherapy or in combination, in advanced solid tumours. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial For patients with high-risk prostate cancer, radiotherapy at a total dose of 80 Gy, in combination with long-term ADT, improved progression-free survival and could be a potential option in this situation. However, given the low number of events, further research is needed to consolidate and confirm the benefit in dose-escalation in prostate cancer-specific survival and overall survival. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial Standardised manual sTIL scoring was reproducible, and digital and AI-based methods showed consistent prognostic stratification and potential for treatment-benefit stratification despite only modest correlation between platforms. AI spatial metrics provided complementary information beyond sTIL density and could support more scalable immune assessment. Future studies are needed to validate these approaches in independent cohorts and to clarify their clinical utility for stratifying contemporary HER2-directed therapies. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study Two cTIL models deployed entirely without retraining or modification provided statistically significant prognostic information and improved risk discrimination compared with clinicopathological variables alone in this large, platform-based, independent validation study. Although cTIL score did not incrementally improve prognostication compared with models combining clinicopathological variables with sTIL score, these findings support the application of cTILs as a reproducible prognostic biomarker, particularly in settings where routine or widespread pathologist assessment is unavailable. Tue, 01 Sep 2026 00:00:00 -0700
[Policy Review] Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient selection and local treatment strategies. This project, endorsed by US and European surgical and radiation oncology societies, aimed to gather expert consensus on these issues. A questionnaire on second iBCE local treatment was developed and reviewed by a core group of eight experts, and Delphi methodology was applied over two rounds to 36 panellists, including radiation oncologists, breast surgeons, a plastic surgeon, and medical physicists. Wed, 29 Jul 2026 22:30:02 +0000
[Review] Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group Tumour-infiltrating lymphocytes (TILs) are prognostic and predictive biomarkers in breast cancer. High pre-treatment TILs are associated with a favourable prognosis and improved response to systemic therapies. However, the role of TILs in mediating response to radiotherapy in breast cancer remains underexplored, with scarce clinical evidence to date. In this Review, we present an overview of current evidence and potential mechanisms, highlight opportunities for integrating TILs into radiation oncology trials and clinical practice, and call for standardised TIL reporting to accelerate biomarker-driven individualisation of radiotherapy in breast cancer. Tue, 01 Sep 2026 00:00:00 -0700
[Personal View] Challenges in the use of the European Society for Radiotherapy and Oncology–European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer The oligometastatic disease classification system, developed within the European Society for Radiotherapy and Oncology (ESTRO)–European Organisation for Research and Treatment of Cancer (EORTC) OligoCare project, has been proposed for prognostic stratification and clinical trial design across solid tumours. Its application to ovarian cancer, however, is challenged by two disease-specific features: early and often diffuse peritoneal spread and the difficulty of lesion enumeration when peritoneal deposits are not discretely measurable. Tue, 01 Sep 2026 00:00:00 -0700
|
Gynecologic cancers in low‐ and middle‐income countries: Bridging the survival gap
Mon, 24 Aug 2026 00:01:16 -0700 Beyond risk factors: A capacity framework for cancer survivorship research Thu, 20 Aug 2026 02:27:05 -0700 Issue Information Thu, 20 Aug 2026 00:00:00 -0700 |
||
|
| |||
|
[Editorial] Sex and gender inequality in classical haematology: time to act
Women, girls, and people assigned female at birth still face major shortfalls in health care because of their sex and gender, and classical haematology is no exception. A major disparity between males and females is the much longer time that females wait to be diagnosed with a bleeding disorder (2 years in males vs 14–16 years in females) leading to untreated chronic and acute bleeding events that can be debilitating and even life threatening. Other challenges that affect physiological processes unique to women, girls, and people assigned female at birth include under-recognition of heavy menstrual bleeding, inconsistent definitions and management plans for post-partum haemorrhage, and poor optimisation of hormone therapy and anticoagulation in hormone therapy-associated and pregnancy-associated thrombosis. Mon, 13 Jul 2026 02:30:02 +0000
[Comment] Expanding access to menstrual health: areas for attention Improving access to menstrual health requires expanded attention and investment in a diversity of areas grounded in its definition. These areas range from increasing menstrual health literacy to commonplace menstrual-friendly public toilets, menstrual-supportive schools, workplaces, and public spaces, as well as improved preventive care and treatment from menarche to menopause, including the recognition that heavy menstrual bleeding occurs frequently in patients with bleeding disorders. The Lancet Haematology Commission1 by Luuk J J Scheres and colleagues highlights crucial areas needing attention for a range of menstrual health-related issues. Mon, 13 Jul 2026 02:30:03 +0000
[News] European Hematology Association 2026 Congress Maria Bouzani (Athens, Greece) and colleagues presented results from a phase 1b study (NCT04884035) assessing the safety and preliminary activity of golcadomide (first-in-class, oral Cereblon E3 Ligase Modulatory Drug) plus polatuzumab-RCHP in patients with newly diagnosed aggressive B-cell lymphoma. 57 patients received the regimen for six 21-day cycles; in the dose-escalation phase, golcadomide was dosed at 0·2 mg (n=28) or 0·4 mg (n=29) orally on days 1–7, and in the dose-expansion phase, patients were randomly assigned to either dose. Wed, 08 Jul 2026 22:30:01 +0000
[In Focus] Emergency obstetric care training for the prevention and management of postpartum haemorrhage in sub-Saharan Africa Postpartum haemorrhage remains a leading cause of maternal mortality worldwide, accounting for 27% of global maternal deaths with approximately 80% of related deaths occurring in low-income and middle-income countries (LMICs), particularly in sub-Saharan Africa and south Asia. Multiple systemic factors, including shortages of skilled health personnel, limited access to antenatal care, delays in referral, inadequate supplies of essential medicines and commodities, and insufficient blood transfusion services contribute to the incidence of postpartum haemorrhage and its associated poor outcomes. Mon, 13 Jul 2026 02:30:02 +0000
[In Focus] Between rules and reality During my transition as a transgender individual, I experienced something that I had been warned about in advance. Deep down I had always thought that will not happen to me. My health-care team had warned me that the medication, especially the hormones containing oestradiol, could increase the risk of dangerous blood clots. I heard the words they said, I realised what they meant, yet it felt far away. On the one hand, I realised there were risks and I did not want to seem self-focused to those around me and wanted to make a responsible choice. Mon, 13 Jul 2026 02:30:02 +0000
[Articles] Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group To our knowledge, this is the largest study on HCT for Hodgkin lymphoma in recent years, and our findings that outcomes after auto-HCT and allo-HCT improved over time provide relevant information that could set the basis for prospective trials or additional studies. Sat, 01 Aug 2026 00:00:00 -0700
[Articles] Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial Low-dose ruxolitinib, used in place of mycophenolate mofetil within a backbone of prophylactic antithymocyte globulin, calcineurin inhibitor, and short-course methotrexate, reduced grade II–IV acute GVHD by day 100 after haploidentical HSCT and had manageable toxicity. These findings support further evaluation of targeted JAK1/2 inhibition as part of GVHD prophylaxis. Sat, 01 Aug 2026 00:00:00 -0700
[Articles] Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study Venetoclax with high-dose cytarabine is active with acceptable safety in paediatric patients with relapsed or refractory AML. These findings support ongoing research of venetoclax with high-dose cytarabine in this population, including the randomised paediatric phase 3 trial (NCT05183035). Wed, 08 Jul 2026 22:30:04 +0000
[The Lancet Haematology Commissions] Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission Women and girls, who make up more than 50% of the population worldwide, lag behind men in a long list of health metrics, with a higher burden of morbidity-driven conditions, undertreatment of pain, and delayed diagnoses.1,2 In particular, women and girls have unique presentations and consequences of haematological disorders, with higher rates of anaemia, unique and greater symptom burden from bleeding disorders due to sex-specific bleeding challenges, and pregnancy-related thrombotic and bleeding complications. Mon, 13 Jul 2026 02:30:02 +0000
[Clinical Picture] Faggot cells in pericardial fluid A man aged 46 years with no history of cardiac disease presented with pancytopenia to Osaka General Medical Center, Osaka, Japan, in June 2025. Bone marrow examination confirmed a diagnosis of acute promyelocytic leukaemia. The PML–RARA rearrangement was identified through RT-PCR. Laboratory data indicated low-risk disease based on the Sanz score (leucocytes 0·6 × 109 cells/L and platelets 42 × 109 cells/L). Induction therapy with all-trans retinoic acid (ATRA; 45 mg/m2 per day given orally) was initiated. Sat, 01 Aug 2026 00:00:00 -0700
|
Bispecific CAR T for extramedullary myeloma: a minute waltz
Volume 148, Issue 7 August 13 2026 NOTCHing the MSC-endothelial interplay in the HSC niche Volume 148, Issue 7 August 13 2026 IKAROS descent and rise of lenalidomide-associated B-ALL Volume 148, Issue 7 August 13 2026 Granulopoiesis under attack by mutant IDH1 Volume 148, Issue 7 August 13 2026 Precision targeting of fetal hemoglobin repressors Volume 148, Issue 7 August 13 2026 Pound wise, penny foolish: improving value in SCD care Volume 148, Issue 7 August 13 2026 Biosimilars approved for hematology use: lessons from comparative efficacy studies and comparative analytical assessments Since the first approval of a filgrastim product in 2015, many biosimilars have come on the marker for hematology indications. Herndon, Brahme, and Ricci present the scientific rationale for replacing comparative efficacy studies, previously used by the US Food and Drug Administration for approvals, with comparative analytical assessments, arguing that modern analytical methods are more sensitive than clinical trials for detecting meaningful differences between biosimilars and reference products. They highlight how this regulatory shift could accelerate biosimilar availability for hematologic malignancies while reducing unnecessary clinical studies.
Volume 148, Issue 7 August 13 2026 How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure In patients with hypocellular bone marrow failure (BMF), disease-specific somatic alterations can help distinguish among different etiologies, including immune-mediated aplastic anemia, inherited BMF syndromes, and hypoplastic myelodysplastic syndrome. Groarke, Gutierrez-Rodrigues, and Patel discuss how they incorporate somatic alterations into their diagnostic approach. Through a series of illustrative cases, they demonstrate how these alterations can also predict the risk of secondary myeloid neoplasms, guide surveillance strategies, and, for selected patients, facilitate early therapeutic intervention.
Volume 148, Issue 7 August 13 2026 Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease Patients with relapsed or refractory multiple myeloma and extraosseous extramedullary disease have poor outcomes. Zhou et al report dual-targeted anti-BCMA/GPRC5D chimeric antigen receptor (CAR) T cells that achieve an overall response rate of 97%, universal bone marrow measurable residual disease negativity among responders, and a stringent complete response rate of 43%, with toxicities comparable to those of single-target CAR T-cell products. Despite these impressive early responses, durability remains limited, highlighting the challenge of achieving long-term disease control in this high-risk population.
Volume 148, Issue 7 August 13 2026 Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals Hematopoietic stem cells (HSCs) rely on specialized niche cells for their maintenance, and the coordinated interactions among these cellular regulators are essential for sustaining hematopoiesis. Xu et al provide evidence that cross talk between endothelial cells (ECs) and mesenchymal stromal cells (MSCs) through Notch signaling is required to maintain HSCs and promote regeneration of the hematopoietic system after injury. Their study identifies a critical role for Notch signaling in mediating EC-MSC communication and regulating HSC function, while reinforcing previous observations that Notch signaling is a central regulator of angiogenesis, osteogenesis, and hematopoiesis.
Volume 148, Issue 7 August 13 2026 IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma Lenalidomide treatment for multiple myeloma is associated with an increased risk of secondary B-cell acute lymphoblastic leukemia (B-ALL). Horns et al performed a comprehensive molecular characterization of 57 cases, demonstrating that IDH2 mutations are highly enriched in lenalidomide-associated B-ALL (23%). Their analyses suggest that these mutations were selected from preexisting clonal hematopoiesis, underscoring the need for continued investigation into the interplay between immunomodulatory therapies and the risk of clonal hematopoiesis progressing to overt leukemia.
Volume 148, Issue 7 August 13 2026 Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs The mechanisms by which IDH1 mutations promote acute myeloid leukemia (AML) remain incompletely understood. Hakobyan et al demonstrate that mutant IDH1 induces an early neutrophil differentiation block through epigenetic repression of Cebpe, defining a key mechanism linking IDH1 mutations to leukemogenesis. These findings identify potential biomarkers and therapeutic targets for IDH1-mutant AML.
Volume 148, Issue 7 August 13 2026 Dissecting polycomb complexes for enhanced fetal hemoglobin production Polycomb repressive complex 1 (PRC1) and PRC2 regulate the fetal-to-adult hemoglobin switch, and reversing this process is a promising therapeutic strategy for sickle cell disease and β-thalassemia. Kaminski et al use a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.
Volume 148, Issue 7 August 13 2026 Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis With the availability of 2 commercial gene therapies and improved outcomes with haploidentical transplantation, patients with sickle cell disease (SCD) now have several potentially curative treatment options. Chetlapalli et al report a cost-effectiveness analysis comparing nonmyeloablative haploidentical transplantation, gene therapy, and standard care in adults and children with SCD. At current prices, haploidentical transplantation is the most cost-effective strategy. This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as Kelkar and Antin conclude in their accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values.
Volume 148, Issue 7 August 13 2026 ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia Next-generation sequencing (NGS) FLT3-internal tandem duplication (ITD) measurable residual disease (MRD) testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. Hourigan et al provide important laboratory and clinical recommendations regarding such testing, focusing on how and when to do it as well as how to interpret the results.
Volume 148, Issue 7 August 13 2026 Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. Blood. 2022;140(15):1686-1701. Volume 148, Issue 7 August 13 2026 Abro B, Maurer MJ, Habermann TM, et al. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis. Blood. 2024;144(19):2063-2066. Volume 148, Issue 7 August 13 2026 |
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents
Sun, 23 Aug 2026 05:14:18 -0700 Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy Sat, 22 Aug 2026 04:21:06 -0700 Clinically Relevant Outcomes With Romiplostim in Patients With Solid Tumors and Persistent Chemotherapy Induced Thrombocytopenia Fri, 21 Aug 2026 02:50:10 -0700 Myeloma Progression Without Osteolysis: Rethinking Whole‐Body Low‐Dose CT Criteria for Bone Disease Thu, 20 Aug 2026 02:19:07 -0700 Hypomethylating Therapy in VEXAS Syndrome: Disease Modification Beyond Bridging to Transplant Wed, 19 Aug 2026 20:44:48 -0700 Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management Tue, 18 Aug 2026 21:58:30 -0700 Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care Fri, 14 Aug 2026 19:25:08 -0700 Current Treatment Landscape and Advances in Lymphoma in China: A Special Issue Thu, 13 Aug 2026 23:16:31 -0700 Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study Thu, 13 Aug 2026 00:30:32 -0700 Hematopoietic Stem Cell Transplantation in Children With Transfusion Dependent β‐Thalassemia: A Two‐Decade Single‐Center Experience Wed, 12 Aug 2026 21:21:58 -0700 2026 Update on Clinical Trials in β‐Thalassemia Wed, 12 Aug 2026 05:31:10 -0700 Real‐World Outcomes of Venetoclax‐Based Therapy in Treatment‐Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study Mon, 10 Aug 2026 07:22:22 -0700 Targeted Next‐Generation Sequencing of JAK2, CALR, and MPL in 10 326 Patients With Suspected Myeloproliferative Neoplasm Sun, 09 Aug 2026 23:45:14 -0700 Undetectable Hydroxyurea in an Untimed Blood Sample Does Not Establish Nonadherence Sun, 09 Aug 2026 22:48:25 -0700 Monoclonal Gammopathy of Thrombotic Significance Sun, 09 Aug 2026 18:57:45 -0700 Unique Aspects of Allogeneic Hematopoietic Stem Cell Transplantation in VEXAS Syndrome: One Size Does Not Fit All Thu, 06 Aug 2026 06:20:29 -0700 Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations Tue, 04 Aug 2026 09:31:59 -0700 Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment? Mon, 03 Aug 2026 05:43:50 -0700 Issue Information Sat, 01 Aug 2026 04:18:05 -0700 Correction to “Polygenic Variation Underlying Neutrophil Counts Modifies the Penetrance of Duffy‐Null Neutropenia” Sat, 01 Aug 2026 04:18:05 -0700 The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN) Sat, 01 Aug 2026 04:18:05 -0700 |
|
|
| |||
|
Thrombin reprograms endothelial extracellular vesicles August 11 2026 - Volume 10, Issue 15 The light chain hunt: appraising assays in AL amyloidosis August 11 2026 - Volume 10, Issue 15 Glowing evidence: radiation shines in early NLPHL August 11 2026 - Volume 10, Issue 15 “Immunologic dream team”: BiTEs periallotransplant to redirect donor lymphocytes toward GVL August 11 2026 - Volume 10, Issue 15 Novel therapies for von Willebrand disease August 11 2026 - Volume 10, Issue 15 CRISPR application in hematological disorders: from bench to bedside August 11 2026 - Volume 10, Issue 15 Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis: a systematic review and meta-analysis August 11 2026 - Volume 10, Issue 15 Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma August 11 2026 - Volume 10, Issue 15 Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial August 11 2026 - Volume 10, Issue 15 HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis August 11 2026 - Volume 10, Issue 15 Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post–CAR T approval era August 11 2026 - Volume 10, Issue 15 Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses August 11 2026 - Volume 10, Issue 15 Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO August 11 2026 - Volume 10, Issue 15 PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia August 11 2026 - Volume 10, Issue 15 Early neurologic response predicts outcomes after anakinra for immune effector cell–associated neurotoxicity syndrome August 11 2026 - Volume 10, Issue 15 Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma August 11 2026 - Volume 10, Issue 15 PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia August 11 2026 - Volume 10, Issue 15 DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia August 11 2026 - Volume 10, Issue 15 ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia August 11 2026 - Volume 10, Issue 15 Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study August 11 2026 - Volume 10, Issue 15 Patient and oncologist expectations of functional prognosis among older adults with acute myeloid leukemia August 11 2026 - Volume 10, Issue 15 A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib August 11 2026 - Volume 10, Issue 15 Thrombin concentration shapes endothelial extracellular vesicle profiles with divergent inflammatory functions August 11 2026 - Volume 10, Issue 15 A long first intron of PROS1 modulates protein S expression across tissues in mice and humans August 11 2026 - Volume 10, Issue 15 Effect of PCC on thrombin generation in patients on FXaI with bleeding or needing urgent surgery (GAUGE) August 11 2026 - Volume 10, Issue 15 Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT August 11 2026 - Volume 10, Issue 15 Hematologic responses achieved with luspatercept in higher-risk myelodysplastic syndromes August 11 2026 - Volume 10, Issue 15 RUNX1+23 enhancer marks erythro-megakaryocyte lineages in early waves of hematopoiesis in human ESC differentiation August 11 2026 - Volume 10, Issue 15 Synthetic lethality in TP53-mutant acute myeloid leukemia August 11 2026 - Volume 10, Issue 15 Clinical care and research gaps in iron deficiency August 11 2026 - Volume 10, Issue 15 Commentary on cost-effectiveness of IV vs oral iron August 11 2026 - Volume 10, Issue 15 Implementing CHARM in transplant practice August 11 2026 - Volume 10, Issue 15 Wang L, Wang J, Li J, Coller BS. A monoclonal antibody to platelet αIIbβ3 that inhibits protein disulfide isomerase binding and platelet aggregation. Blood Adv. 2026;10(9):3172-3185. August 11 2026 - Volume 10, Issue 15 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Azithromycin for Preschoolers with Wheezing in the Emergency Department
New England Journal of Medicine, Volume 395, Issue 8, Page 753-764, August 20/27, 2026.
Survodutide Once Weekly for the Treatment of Adults with Obesity New England Journal of Medicine, Volume 395, Issue 8, Page 776-787, August 20/27, 2026.
Myeloproliferative Neoplasms New England Journal of Medicine, Volume 395, Issue 8, Page 788-802, August 20/27, 2026.
Oral Ivermectin and 5% Permethrin Cream for Severe Scabies New England Journal of Medicine, Volume 395, Issue 8, Page 829-830, August 20/27, 2026.
Biologic Ventricular Assist Tissue in Heart Failure New England Journal of Medicine, Volume 395, Issue 8, Page 827-829, August 20/27, 2026.
Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression New England Journal of Medicine, Volume 395, Issue 8, Page 825-827, August 20/27, 2026.
Antiretroviral Therapy New England Journal of Medicine, Volume 395, Issue 8, Page 832-832, August 20/27, 2026.
Mucolytics in Respiratory Failure — A MARCH Forward New England Journal of Medicine, Volume 395, Issue 8, Page 817-818, August 20/27, 2026.
Drug-Induced Subacute Cutaneous Lupus Erythematosus New England Journal of Medicine, Volume 395, Issue 8, August 20/27, 2026.
Case 24-2026: A 74-Year-Old Man with Dyspnea, Proximal Muscle Weakness, and Hypoxemia New England Journal of Medicine, Volume 395, Issue 8, Page 804-815, August 20/27, 2026.
Crew Resource Management — Navigating AI’s Automation Paradox New England Journal of Medicine, Volume 395, Issue 8, Page 731-734, August 20/27, 2026.
Marijuana Rescheduling — A Game Changer for Research? New England Journal of Medicine, Volume 395, Issue 8, Page 729-731, August 20/27, 2026.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy New England Journal of Medicine, Ahead of Print.
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema New England Journal of Medicine, Ahead of Print.
Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty New England Journal of Medicine, Ahead of Print.
Andes Virus — A Clinical Review New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
About the cover image
Issue Highlights Redefining the Limits of Highly Conformal Radiation Therapy for Brain Metastases A Sticky Situation: 4th Recurrence of Rectal Mucinous Adenocarcinoma Fourth Time's the Charm? Pushing the Limits of Hyperfractionated Reirradiation in Recurrent Rectal Cancer Never Say Never: Another Opportunity for Curative-Intent Preoperative Pelvic Reirradiation Creating Space for Dose Escalation: A Strategy for Pelvic Reirradiation Unsticking the Situation: Multidisciplinary Precision Salvage for a Fourth Rectal Recurrence Radiation Therapy Accessibility in Cambodia and Mongolia — Geospatial Modeling Analysis in Low- and Middle-Income Countries Within the Asia-Pacific Region One more measurement before I go… Competency-Based Simulation and Evaluation in Medical Education: Clinical Decision Making and Reference Dosimetry Reporting and Outcomes of Brachytherapy for Gynecologic Reirradiation: A Systematic Review Improving Treatment of Radiation-Induced Premature Ovarian Insufficiency After Cervical Cancer: A Practice Quality Improvement Initiative Dosimetric Predictors of Sexual Toxicity in Cervical Cancer Patients Treated With Definitive Chemoradiation and Magnetic Resonance Imaging-Guided Brachytherapy Constraints, Cumulative Doses, and Toxicity Outcomes in Glioma Reirradiation: A Systematic Review and Radiobiological Comparison From the Reirradiation Collaborative Group (ReCOG) A New Predictive Model for Radiation Necrosis Risk Based on PTV-Enriched Blood Inflammatory Biomarkers in Patients With Brain Metastases Treated With Stereotactic Radiosurgery Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial Combined Real-time Liquid Biopsy With TNM Stage to Guide Induction Chemotherapy Cycles in Nasopharyngeal Carcinoma: A Development and Validation Study Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial Prophylactic Recombinant Human Thrombopoietin Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiation Therapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Phase II Clinical Trial Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management A Critique of the DCISionRT Test On the Road to Personalized Treatment Decision-Making for Patients With Ductal Carcinoma In Situ Pushing the Boundaries of Stereotactic Body Radiation Therapy in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study Beyond the “Swan Song”: Salvage Stereotactic Body Radiation Therapy for Nodal Oligorecurrence in Previously Irradiated Prostate Cancer – Lessons From the CYGNUS Retrospective Study Opposing Two-Fraction Regimens Combining Low and High Doses of Ionizing Radiation Elicit Differential Immune Responses Voxel-based Analysis Identifies New Functional Subregions Predictive of Xerostomia After Head and Neck Cancer Radiation Therapy Comparison of Computed Tomography Ventilation Imaging and Hyperpolarized 3He Magnetic Resonance Imaging in Patients With Lung Cancer Cognitive Outcomes After Radiation Therapy for Medulloblastoma: A Voxel-based Analysis Pretreatment Radiation Esophagitis Prediction Using Quantum Machine Learning in Patients With Esophageal Cancer Multi-lead Monitoring to Deduce Translations and Rotations of the Heart Through Respiration and Its Geometric Implications for Motion Management in Cardiac Radioablation A Longitudinal Assessment of Remote IMRT/VMAT Training for Medical Physicists in Low- and Middle-Income Countries |
Being Artificially Intelligent September 2026: 69(9):2223-2225 How Much Does It Cost to Become a Colorectal Surgeon? A Cost Comparison of Training in the United States, Australia and New Zealand, and the United Kingdom September 2026: 69(9):2226-2229 Artificial Intelligence for Colorectal Surgeons—Part I: Foundations and Clinical and Educational Applications September 2026: 69(9):2230-2240 Herrmann and Desfosses, the 2 Men “Behind the Anal Glands”: A Brief Account of a Notable Page in the History of Proctology September 2026: 69(9):2241-2247 Managing Reach Limitations in Left-Sided Colectomy September 2026: 69(9):2248-2251 Expert Commentary on Managing Reach in Colectomy: Achieving a Tension-Free Anastomosis September 2026: 69(9):2252-2253 Oncologic Outcomes of Robot-Assisted Upfront Surgery Using a Fascia-Guided Total Mesorectal Excision Strategy for T3 Rectal Cancer September 2026: 69(9):2254-2265 Risk Factors for Small-Bowel Crohn’s Disease Recurrence After Total Proctocolectomy September 2026: 69(9):2266-2272 Sexual Distress Is Common in Long-term Follow-up After Pelvic Pouch for Ulcerative Colitis: A Cross-Sectional Study September 2026: 69(9):2273-2282 End-to-Side Ileocolonic Anastomosis After Ileocecectomy for Crohn’s Disease Is a Safe Option With Low Recurrence September 2026: 69(9):2283-2290 Quadratus Lumborum Block During Minimally Invasive Colorectal Surgery: A Tool for Enhanced Recovery September 2026: 69(9):2291-2300 Risk of Metabolic Disease After Right- Versus Left-Sided Colectomy for Colon Cancer: A Nationwide Cohort Study September 2026: 69(9):2301-2311 Cost-Effectiveness of Pelvic Floor Reconstruction Using Biological Mesh After Extralevator Abdominoperineal Resection for Rectal Cancer September 2026: 69(9):2312-2320 Patient-Level Socioecological Comorbidities and Time to Initiation of Curative-Intent Treatment for Colorectal Cancer September 2026: 69(9):2321-2331 Selected Abstracts September 2026: 69(9):2332-2336 Managing Reach Problems in Pouch Surgery: Lengthening Maneuvers and S-Pouch Creation September 2026: 69(9):2337-2337 Artificial Intelligence–Assisted Anatomical Recognition System-Guided Robotic Total Mesorectal Excision and Autonomic Nerve Preservation for Rectal Neuroendocrine Tumor September 2026: 69(9):2338-2338 Simultaneous Application of Robotic Surgery and Transanal Minimally Invasive Surgery Platform in the Context of Sphincter Preservation, Stepwise Description September 2026: 69(9):2339-2339 Robotic Lateral-to-Medial Left Colon Dissection: A Technical Approach for Total Mesorectal Excision September 2026: 69(9):2340-2342 Single-Port Robotic Transstomal End Colostomy Resection and Closure September 2026: 69(9):2343-2344 |
||
|
| |||
|
Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer
Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study led by Amy L. Shaver, PhD, PharmD, MPH, and... The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study,... Monday, August 24, 2026 11:12 AM Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery A short-term, intensive weight-loss program before surgery was feasible and produced meaningful weight loss in women with endometrial cancer and excess weight in the randomized ENDO-CARE trial. The intervention was also associated with fewer postoperative complications, although the study was not... ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases Circulating tumor DNA (ctDNA) for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to findings from an overall survival analysis of the phase II GALAXY... Friday, July 17, 2026 1:00 PM Technology-Enabled Intervention for HCT Recipients, Primary Care Doctors May Improve Skin Cancer Screening Recipients of hematopoietic cell transplant (HCT) are at increased risk of skin cancer and screening for early detection is encouraged. New research published by Armenian et al in JNCCN—Journal of the National Comprehensive Cancer Network shows how a technology enabled, remotely delivered,... Monday, August 10, 2026 10:25 AM FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices The U.S. Food and Drug Administration (FDA) has released a discussion paper regarding factors that go into the regulation of generative artificial intelligence (AI)–enabled medical devices and is asking for public feedback, focusing on areas such as risk assessment, premarket evaluation, and... Friday, August 21, 2026 12:00 PM Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality Flight attendants and pilots had the highest and second-highest risk-adjusted percentages of deaths from radiation-related cancers, respectively, among more than 500 occupations in the United States, according to the results of a population-based analysis reported by Patel et al in a research... INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma Friday, August 21, 2026 11:29 AM Early Histotripsy Use for Liver Tumors Raises Questions About Patient Selection Histotripsy was cleared by the U.S. Food and Drug Administration in 2023 for the treatment of primary and metastatic liver tumors. In a research letter published in JAMA Network Open, Sears et al reported findings from a retrospective cohort study evaluating national practice patterns and... Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL According to the results of a phase II study reported by Lynch et al in the Journal of Clinical Oncology, a chemotherapy-free approach using subcutaneous single-agent mosunetuzumab, or, for patients without an initial complete response, mosunetuzumab followed by polatuzumab vedotin plus... Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors A personalized approach to obesity treatment may help breast cancer survivors improve their long-term health by identifying early which patients need more than behavioral lifestyle intervention alone. Thursday, August 20, 2026 10:55 AM County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults Individuals diagnosed with cancer in the United States often bear significant health-care costs and productivity losses, with over half incurring cancer-related medical debt. In response, cancer patients and survivors often delay or forgo necessary care; cut back on food, clothing, and basic... Thursday, August 20, 2026 10:41 AM Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals AI is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, 2026, Cleveland Clinic in collaboration with the College of Healthcare Information Management Executives (CHIME), will host the Second ... Thursday, August 20, 2026 10:30 AM Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events The addition of radium-223, an alpha-emitting bone-seeking radioisotope, to cabozantinib, a tyrosine kinase inhibitor, did not improve skeletal-related outcomes in patients with metastatic renal cell carcinoma and bone metastases, according to findings from the randomized phase II RADICAL trial... Wednesday, August 19, 2026 11:30 AM Charles W.M. Roberts, MD, PhD, Named President and Chief Executive Officer of St. Jude Children’s Research Hospital The Board of Governors of St. Jude Children’s Research Hospital have announced Charles W.M. Roberts, MD, PhD, Executive Vice President and current Director of the St. Jude Comprehensive Cancer Center, as its next President and Chief Executive Officer. The announcement follows an extensive... Wednesday, August 19, 2026 11:13 AM Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer? Among patients with early breast cancer receiving aromatase inhibitors, excess adiposity emerged as a novel risk factor for vertebral fracture progression, whereas higher muscle mass was protective, according to a retrospective cohort study by Schivardi et al published in JAMA Network Open. Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer Tumor genomic alterations and transcriptomic subtypes may provide prognostic information in patients with resected pancreatic ductal adenocarcinoma (PDAC), but most did not predict differential benefit from adjuvant modified FOLFIRINOX (mFOLFIRINOX) vs gemcitabine, according to an analysis of the... Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall survival vs tislelizumab plus chemotherapy in patients with previously untreated advanced squamous... Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC As reported in The Lancet Oncology by Brunetti et al, a post hoc analysis of the phase III PACIFIC trial showed that baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes among patients with unresectable stage III non–small cell lung cancer (NSCLC)... Consumption of Sugar-Sweetened Beverages May Raise Gastric Cancer Risk Approximately 65% of U.S. adults report consuming one or more sugar-sweetened beverages every day. Researchers found that consuming these drinks daily was associated with an increased risk of developing gastric cancer, whereas consumption of artificially sweetened beverages was not associated with... Tuesday, August 18, 2026 10:44 AM High-Risk ERBB2-Negative Breast Cancer: Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy The addition of dual PD-1 and LAG-3 inhibition with cemiplimab-rwlc and fianlimab to standard paclitaxel-based neoadjuvant chemotherapy resulted in improved pathologic complete response rates in patients with early-stage, high-risk ERBB2 (formerly HER2 or HER2/neu)-negative breast cancer, according ... TACE Plus Thermal Ablation Improves Survival in Unresectable HCC Transarterial chemoembolization (TACE) followed by thermal ablation was associated with improved survival outcomes compared with TACE alone in patients with liver-confined, unresectable hepatocellular carcinoma, according to findings from the phase III TORCH trial published by Lyu et al in JAMA... AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC The American Association for the Study of Liver Diseases (AASLD) recently announced the publication of BEACON-HCC, a landmark multidisciplinary consensus now available online in HEPATOLOGY. Monday, August 17, 2026 10:43 AM AI Model Predicts TP53 Status, Tumor Type, and Survival From Routine H&E Slides Using an artificial intelligence (AI) model, researchers were able to simultaneously predict cancer subtype, TP53 mutation status, and survival outcomes across 32 solid tumors from routine hematoxylin and eosin (H&E)–stained whole-slide images, according to findings published in The American... Monday, August 17, 2026 10:00 AM Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer In the phase III ARISTOTLE trial, adding irinotecan to preoperative capecitabine-based chemoradiotherapy did not improve disease-free survival in patients with locally advanced rectal cancer, and was also associated with substantially more severe toxicity. The findings were reported by... |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Exploring the landscape of targetable alterations in patients with glioblastoma
Despite considerable progress in other cancer types, progress with the development of targeted therapies for patients with glioblastoma has remained limited, despite considerable research effort. In this Review, the authors summarize the various attempts to develop effective targeted therapies for patients with glioblastoma, including some of the challenges that have likely impaired progress thus far. The authors also highlight novel therapies, clinical trial designs and research directions that have been informed by the shortcomings of previous research efforts, all of which might eventually lead to improved outcomes for patients. Wed, 19 Aug 2026 00:00:00 -0700 Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma The phase III FIGHT-302 trial demonstrated that the FGFR inhibitor pemigatinib improves progression-free survival and response rates versus first-line chemotherapy in patients with advanced-stage FGFR2-rearranged cholangiocarcinoma. However, the trial accrued slowly and closed early after chemoimmunotherapy became the new standard of care. FIGHT-302, alongside two similarly terminated trials, highlights the need for innovative trial designs and flexible regulatory frameworks to evaluate therapies in rare, biomarker-defined populations. Wed, 12 Aug 2026 00:00:00 -0700 How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease PROTEUS met its amended co-primary end points but should not be interpreted as practice changing. The trial compared two experimental strategies rather than the current standard of care, relied on an unvalidated approach (prostate-specific membrane antigen-PET) for assessments of metastasis-free survival, demonstrated minimal absolute benefit with increased toxicity and lacks both mature overall survival data and sufficient data on patient-reported outcomes to support adoption. Tue, 11 Aug 2026 00:00:00 -0700 The proteome comes of age, but precision oncology needs functional maps Yue and colleagues present a landmark anatomical atlas of human protein abundance across non-malignant tissues and cancers. We argue that precision oncology needs functional proteomic maps that add signalling activity, post-translational modifications, pathology-guided compartment resolution, metastatic and longitudinal sampling, clinical annotation and population diversity to make proteomics therapeutically actionable. Mon, 10 Aug 2026 00:00:00 -0700 HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL Fri, 07 Aug 2026 00:00:00 -0700 AI-based augmentation of oncology clinical trials Oncology clinical trials are characterized by high failure rates — reflecting both the biological complexity of cancer and operational inefficiencies — and the generalizability of their results is often limited. In this Review, the authors discuss opportunities to address these limitations via application of artificial intelligence tools across the lifecycle of clinical trials as well as key challenges that must be overcome for routine clinical deployment of these tools. Fri, 07 Aug 2026 00:00:00 -0700 Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC Tue, 04 Aug 2026 00:00:00 -0700 More options, more questions in the management of early relapsed and/or refractory multiple myeloma In MonumenTAL-3, the G-protein-coupled receptor class C group 5 memberD-directed bispecific T cell engager talquetamab combined with either daratumumab or daratumumab–pomalidomide conferred significantly longer progression-free survival than daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma (≥1 prior line of therapy). These results herald a new therapeutic option for such patients but also raise questions regarding how talquetamab-based regimens should be integrated with B cell maturation antigen-directed T cell-redirecting therapies. Fri, 31 Jul 2026 00:00:00 -0700 |
|
|
| |||
|
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Vol 17, No 4 (August 31, 2026): The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence Vol 17, No 4 (August 31, 2026): FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2 Vol 17, No 4 (August 31, 2026): Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study Vol 17, No 4 (August 31, 2026): Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study Vol 17, No 4 (August 31, 2026): Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study Vol 17, No 4 (August 31, 2026): Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study Vol 17, No 4 (August 31, 2026): Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma Vol 17, No 4 (August 31, 2026): Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway Vol 17, No 4 (August 31, 2026): The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study Vol 17, No 4 (August 31, 2026): Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM Vol 17, No 4 (August 31, 2026): Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer Vol 17, No 4 (August 31, 2026): Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study Vol 17, No 4 (August 31, 2026): Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with activation of Hippo signaling pathway Vol 17, No 4 (August 31, 2026): Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer Vol 17, No 4 (August 31, 2026): Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis Vol 17, No 4 (August 31, 2026): Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression Vol 17, No 4 (August 31, 2026): A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators Vol 17, No 4 (August 31, 2026): Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study Vol 17, No 4 (August 31, 2026): Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study Vol 17, No 4 (August 31, 2026): Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression Vol 17, No 4 (August 31, 2026): Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis Vol 17, No 4 (August 31, 2026): Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer Vol 17, No 4 (August 31, 2026): Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study Vol 17, No 4 (August 31, 2026): Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 4 (August 31, 2026): Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study Vol 17, No 4 (August 31, 2026): Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study Vol 17, No 4 (August 31, 2026): A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Vol 17, No 4 (August 31, 2026): Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer Vol 17, No 4 (August 31, 2026): Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Vol 17, No 4 (August 31, 2026): Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study Vol 17, No 4 (August 31, 2026): Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations Vol 17, No 4 (August 31, 2026): Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis Vol 17, No 4 (August 31, 2026): Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior Vol 17, No 4 (August 31, 2026): Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial Vol 17, No 4 (August 31, 2026): Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy Vol 17, No 4 (August 31, 2026): Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection Vol 17, No 4 (August 31, 2026): Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial Vol 17, No 4 (August 31, 2026): Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries Vol 17, No 4 (August 31, 2026): Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database Vol 17, No 4 (August 31, 2026): Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection Vol 17, No 4 (August 31, 2026): Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications Vol 17, No 4 (August 31, 2026): Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis Vol 17, No 4 (August 31, 2026): Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study Vol 17, No 4 (August 31, 2026): A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study Vol 17, No 4 (August 31, 2026): SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023 Vol 17, No 4 (August 31, 2026): Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Vol 17, No 4 (August 31, 2026): Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review Vol 17, No 4 (August 31, 2026): MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review Vol 17, No 4 (August 31, 2026): Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review Vol 17, No 4 (August 31, 2026): From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer Vol 17, No 4 (August 31, 2026): Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial Vol 17, No 4 (August 31, 2026): Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features Vol 17, No 4 (August 31, 2026): Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts Vol 17, No 4 (August 31, 2026): Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility Vol 17, No 4 (August 31, 2026): Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prognostic role of resting heart rate in patients with colorectal cancer Vol 17, No 4 (August 31, 2026): DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation Vol 17, No 4 (August 31, 2026): Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? Vol 17, No 4 (August 31, 2026): Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold Vol 17, No 4 (August 31, 2026): Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting Vol 17, No 4 (August 31, 2026): Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash Vol 17, No 4 (August 31, 2026): Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors Vol 17, No 4 (August 31, 2026): Extending the utility of anti-EGFR therapy in metastatic colorectal cancer Vol 17, No 4 (August 31, 2026): Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity? Vol 17, No 4 (August 31, 2026): Ferroptosis in gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 4 (August 31, 2026): |
|
||
|
| |||
|
Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone
Annals of Internal Medicine, Volume 179, Issue 8, Page 1073-1084, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Prolonged Short Sleep and Its Effect on Body Weight and Composition Annals of Internal Medicine, Volume 179, Issue 8, Page 1085-1093, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Performance of Lung Cancer Risk Prediction Models in Different Racial and Ethnic Groups in the United States: Results From the Lung Cancer Cohort Consortium Annals of Internal Medicine, Volume 179, Issue 8, Page 1094-1106, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 8, Page 1107-1116, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis Annals of Internal Medicine, Volume 179, Issue 8, Page 1117-1127, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 8, Page 1128-1139, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 8, Page 1140-1155, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 8, Page 1156-1168, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Reporting Interest-Holder Engagement in Practice Guidelines: The RIGHT-MuSE Checklist Annals of Internal Medicine, Volume 179, Issue 8, Page 1169-1176, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026) Annals of Internal Medicine, Volume 179, Issue 8, Page 1177-1185, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Visual Guideline - Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Visual Clinical Guideline From the American College of Physicians (April 2026) Annals of Internal Medicine, Volume 179, Issue 8, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 How Would You Manage Perioperative Cardiovascular Risk for Noncardiac Surgery in This Patient With Complex Comorbidity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 8, Page 1186-1196, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Care of Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists Annals of Internal Medicine, Volume 179, Issue 8, Page 1197-1198, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Prior Authorization and Clinical Authority: Time to Recalibrate? Annals of Internal Medicine, Volume 179, Issue 8, Page 1199-1200, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Revitalizing Primary Care Internal Medicine: Addressing the Hidden Curriculum Annals of Internal Medicine, Volume 179, Issue 8, Page 1201-1202, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Treating Obesity With Pharmacotherapy: Making Sense of the Evolving Science When Data Are Vast but Direct Comparative Evidence Is Sparse Annals of Internal Medicine, Volume 179, Issue 8, Page 1203-1205, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Dear Resident Mother Annals of Internal Medicine, Volume 179, Issue 8, Page 1206-1207, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Giving Up Annals of Internal Medicine, Volume 179, Issue 8, Page 1208-1209, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Identifying Meaningful Patient Savings on Generics: Direct-to-Consumer Prices Versus Commercial Insurance Cost Sharing Annals of Internal Medicine, Volume 179, Issue 8, Page 1210-1212, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study Annals of Internal Medicine, Volume 179, Issue 8, Page 1212-1215, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1215-1216, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1216-1217, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1217-1217, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1217-1218, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1218-1218, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1218-1219, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study The Phase 2 study was small and was not designed to establish the statistical difference between Vistagen’s drug candidate and placebo, according to Vistagen. The biotech plans to meet with the FDA to determine a registrational path for the asset.
BioVie shares halve on murky Parkinson’s disease readout BioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.
AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau candidates from Denali Therapeutics, Eisai and Eli Lilly.
AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026 FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer’s Cognition Caliway’s CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 Endeavor BioMedicines to Present Quantitative Image Analysis from Phase 2a Trial of Taladegib (ENV-101) at European Respiratory Society (ERS) Congress 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 |
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion into chronic rhinosinusitis last year.
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia With a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year. If granted market entry, avexitide could hit peak sales of $1.7 billion worldwide, analysts estimate.
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout It’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in depression.
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts Definium Therapeutics’ closely watched anxiety readout could further validate its single-dose LSD candidate, while Compass Pathways advances a psilocybin program through a rolling FDA filing.
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma Caliway’s CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 |
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.
‘Worse than expected’ Wainua data muddies water for TTR silencers AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the standard of care for ATTR-CM, analysts say.
Multispecifics are transforming the CDMO development architecture Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.
Generate Bio drops as data accidentally leaked ahead of European conference Phase 1 data from Generate Biomedicines’ ongoing chronic obstructive pulmonary disease study demonstrated “rapid and sustained reductions” across four disease biomarkers.
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion into chronic rhinosinusitis last year.
Fragile X at a turning point: Breaking through the clinical bottleneck In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.
CDMO hiring tough as demand for specialized talent outpaces supply The talent pool not keeping pace with increased outsourcing demand is just one reason CDMOs have trouble filling roles, according to a search expert. He also told BioSpace who is most in demand and how candidates can stand out from the competition.
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’ Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.
Theralase(R) Releases Q2 2026 Financial Statements Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026 FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Slate Medicines Announces First Participant Dosed in Phase 1 Study Evaluating SLTE-1009 Velocity Clinical Research Establishes a New Industry Benchmark, Entering 97% of Patient Data Within 24 Hours of Collection TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 MicrobiotiX Completes Sentinel Cohort of its First-in-human Clinical Trial of MP101 for Pneumonia |
|
|
| |||
|
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:00:01 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:00:01 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:00:01 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:00:01 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:00:01 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:00:01 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:00:01 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:00:01 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:01 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:01 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:01 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:01 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:01 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:01 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:01 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:01 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:01 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:01 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:01 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:01 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:01 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:01 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:01 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:01 -0700
|
Intraosseous calvarial haematoma mimicking a skull tumour in a child with Noonan syndrome: a case report.
J Surg Case Rep. 2026 Aug 24;2026(8):rjag743. doi: 10.1093/jscr/rjag743. eCollection 2026 Aug. Ibrahim B, Al-Dabbas W, Awad M, Arabyat A, Hiasat M Objective monitoring tools for improved management of childhood asthma. Respir Res. 2024 May 3;25(1):194. doi: 10.1186/s12931-024-02817-y. Au-Doung PLW, Chan JCH, Kui OYH, Ho MKY, Cheung YT, Lam JKW, Chan HK, Brannan J, Chan KCC, Li AM, Leung SSY Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract. 2012 Sep;97(3):483-91. doi: 10.1016/j.diabres.2012.03.012. Epub 2012 Apr 18. Ho JS, Germer S, Tam CH, So WY, Martin M, Ma RC, Chan JC, Ng MC Prehospital epinephrine as a bridge to survival in traumatic cardiac arrest: A nationwide propensity score-matched analysis. Am J Emerg Med. 2026 Jun 24;109:52-57. doi: 10.1016/j.ajem.2026.06.039. Chai HS, Park GJ, Kim YM, Kim SC, Kim H, Lee SW Neuroimaging Abnormalities and Genotype-Phenotype Correlations in Noonan Syndrome: A Multicenter Cohort Study. J Clin Endocrinol Metab. 2026 Aug 27:dgag352. doi: 10.1210/clinem/dgag352. Patti G, Maiorano NG, Piccoli F, Zucconi A, Calevo MG, Tamburrino F, Scarano E, Schiavariello C, Rossi C, Mazzanti L, Orlandini E, Pozzobon G, Finamore M, Baldoli C, Grandone A, Cirillo M, Aiello F, Corica D, Wasniewska M, Cattoni A, Remida P, Capalbo D, Tortora F, Salerno MC, Azzolini S, Mansour M, Faienza MF, Palladino S, Tortora D, Rosti G, Faravelli F, Venturino C, Capuozzo P, De Mori L, Maietta P, Allegri AEM, Morreale C, Angelelli A, Napoli F, Di Iorgi N, Rossi A, Maghnie M, Severino M Sex-specific aging clocks from a large-scale human phenome reveal distinct aging transitions and circulating signatures. Nat Aging. 2026 Aug 25. doi: 10.1038/s43587-026-01180-5. Li J, Gao DD, Li J, Cao L, Du Y, Xiong M, Chu X, Lei W, Ye WD, Xu G, Ma L, Tang J, Fu Q, Zheng Z, Zhao H, Yi M, Lan C, Xu LJ, Fan Y, Zhu G, Xiao L, Zheng Q, Si S, Cheng H, Jiang B, Sun S, Jiang W, Ma S, Zhang H, Wang S, Yang YG, Yang J, Qu J, Zhang F, Liu Z, Zhao G, Liu GH, Zhang W Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry. 2004 Apr;61(4):412-20. doi: 10.1001/archpsyc.61.4.412. McRae C, Cherin E, Yamazaki TG, Diem G, Vo AH, Russell D, Ellgring JH, Fahn S, Greene P, Dillon S, Winfield H, Bjugstad KB, Freed CR Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol. 2026 Sep;27(9):1077-1093. doi: 10.1016/S1470-2045(26)00278-0. Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J; EMERALD-3 Investigators Postural Orthostatic Tachycardia Syndrome (POTS): A Review. JAMA. 2026 Aug 24. doi: 10.1001/jama.2026.14809. Chung TH, Raj SR Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models. J Med Chem. 2019 Dec 12;62(23):10691-10710. doi: 10.1021/acs.jmedchem.9b01143. Epub 2019 Nov 20. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). Bioorg Med Chem. 2016 Feb 15;24(4):521-44. doi: 10.1016/j.bmc.2015.11.045. Epub 2015 Dec 1. Reddy MV, Akula B, Jatiani S, Vasquez-Del Carpio R, Billa VK, Mallireddigari MR, Cosenza SC, Venkata Subbaiah DR, Bharathi EV, Pallela VR, Ramkumar P, Jain R, Aggarwal AK, Reddy EP Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors. Bioorg Med Chem. 2018 May 1;26(8):1740-1750. doi: 10.1016/j.bmc.2018.02.022. Epub 2018 Feb 16. Hou W, Ren Y, Zhang Z, Sun H, Ma Y, Yan B Effect of Workplace Violence on Turnover Intention: The Mediating Roles of Job Control, Psychological Demands, and Social Support. Inquiry. 2020 Jan-Dec;57:46958020969313. doi: 10.1177/0046958020969313. Yeh TF, Chang YC, Feng WH, Sclerosis M, Yang CC On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 Aug 25:S2468-1253(26)00212-8. doi: 10.1016/S2468-1253(26)00212-8. Kudo M, Ogasawara S, Liu R, Gu S, Wang K, Zhao M, Hu H, Liu Z, Lin K, Liu J, Lin Z, Zhang Y, Peng T, Song J, Ueno M, Zhu J, Bai L, Tong L, Shi Y, Han G, Dong J Characteristics of Vaginal Microbiome in Reproductive-Age Females with HPV Infection in Xinjiang, China. Evid Based Complement Alternat Med. 2022 Nov 1;2022:7332628. doi: 10.1155/2022/7332628. eCollection 2022. Xia Y, Feng Y, Qin T, Zhao X, Lu J, Ma C Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1094-1109. doi: 10.1016/S1470-2045(26)00282-2. Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L Childhood trauma and suicide ideation and attempts: Examining the mediating role of psychosocial, personality, lifestyle and biological factors. J Affect Disord. 2026 Aug 25;414:122414. doi: 10.1016/j.jad.2026.122414. Wiebenga JXM, Lokhorst L, Hoogendoorn AW, Heering HD, Eikelenboom M, Giltay EJ, van Oppen P, Penninx BWJH Toward unified and comprehensive automated electroencephalogram interpretation: a multicentre development and validation of an electroencephalogram foundation model. Lancet Digit Health. 2026 Aug 25:101039. doi: 10.1016/j.landig.2026.101039. Sun C, Karakis I, Herlopian A, Ng MC, Osman G, Sheikh Z, Taraschenko O, Yoo JY, Appavu BL, Arcot Jayagopal L, Kaplan PW, Lee JW, Selioutski O, Haider HA, Halford JJ, Hoch DB, Lam A, Nascimento FA, Pathmanathan J, Schmitt S, De Stefano P, Fisch U, Gijs J, Castro-Lima H, Kong WY, Cervenka MC, Dhakar MB, Fatima S, Gaspard N, Gilmore EJ, Herman ST, Holmes MG, Johnson EL, Muniz CF, Rosenthal ES, Rodriguez Ruiz AA, Sarkis RA, Shafi MM, Swisher CB, Tabaeizadeh M, Benbadis SR, Chan F, Chu CJ, Dolatshahi M, Greenblatt AS, Katyal R, Nwankwo C, Amorim E, Tatum WO, Weber D, Loddenkemper T, Peters JM, Katwa U, Maski K, Thomas RJ, Hong S, Yuan D, Cash SS, Cole AJ, Goldenholz DM, Stow C, Kim JA, Zafar SF, Struck AF, Westover MB, Jing J A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan. Nat Aging. 2026 Aug 25. doi: 10.1038/s43587-026-01181-4. Lu X, Ping J, Han Z, Zhang S, Liu L, Xiong M, Fan Y, Li J, Sun X, Yang P, Zheng K, Wang ZK, Ping J, Xiong Y, Zuo Y, Zhang M, Li J, Wu Q, Wang Q, Gao DD, Jiang B, Sun S, Ma S, Wang S, Qu J, Yang YG, Zhang F, Liu GH, Zhang W Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome. JAMA Intern Med. 2026 Aug 24:e263983. doi: 10.1001/jamainternmed.2026.3983. Kaufman RM, Hoen AG, Khan J, Knudson CM, Metcalf RA, Mindiola Romero AE, Mo A, Schäfer R, Takanashi M, Dunbar NM; UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative; Kaufman RM, Hoen AG, Khan J, Knudson CM, Metcalf RA, Mindiola Romero AE, Mo A, Schäfer R, Takanashi M, Afraz S, Allen ES, Andrews J, Aurich K, Casey J, Cohn CS, Cone Sullivan JK, Cousins CC, Crowe EP, De Giorgi V, Delaney M, DelBaugh RM, Gilstad CW, Gofton A, Hendrickson JE, Hill K, Hogan KO, Humbrecht C, Ikeda K, Jacquot C, Javanbakht A, Juskewitch JE, Lu W, Menzies Wojtowicz MM, Miller MJ, Mills G, Nelson AC, Pagano MB, Pauly MC, Poisson JL, Raval JS, Saifee NH, Samy N, Sato T, Takeda Y, Thibodeaux SR, Tiberghien P, van Nunen S, Virk MS, West-Mitchell K, Wood EM, Yamanouchi J, Yoshihara S, Zheng XL, Ziman A, Dunbar NM |
||